Top Reddit Short Squeeze Mentions for Monday August 22, 2022: APRN, PRTY, BBBY, AMC, REV, GME, SNMP, BBIG, MNMD, DNAA
$AMC
$APRN
$BBBY
$BBIG
Movies/Entertainment
Consumer Discretionary
Catalog/Specialty Distribution
Consumer Discretionary
Save time and jump to the most important pieces.
| Company | Date | Price Target | Rating | Analyst |
|---|---|---|---|---|
| 10/14/2024 | $20.00 | Outperform | Leerink Partners | |
| 7/24/2024 | $36.00 | Buy | ROTH MKM | |
| 5/29/2024 | $27.00 | Outperform | Robert W. Baird | |
| 4/15/2024 | $20.00 | Outperform | Leerink Partners | |
| 2/29/2024 | $12.00 → $8.00 | Neutral | B. Riley Securities | |
| 12/5/2023 | $9.00 | Buy | Canaccord Genuity | |
| 9/26/2023 | $15.50 → $4.75 | Sell | Citigroup | |
| 8/24/2023 | $19.00 | Underperform → Neutral | Wedbush |
GRAPEVINE, Texas, Nov. 18, 2024 (GLOBE NEWSWIRE) -- GameStop Corp. (NYSE:GME) ("GameStop" or the "Company") today announced that Nat Turner, Chairman and CEO of Collectors Holdings, Inc., has been appointed to the Company's Board of Directors. Contact GameStop Investor [email protected]
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the appointment of Gregg A. Pratt, Ph.D., as Chief Regulatory and Quality Assurance Officer. Dr. Pratt will serve as a member of the Executive Committee and oversee the Company's regulatory and quality functions, as well as its product registration strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241118653031/en/(Photo: Business Wire) "We are thrilled to welcome Gregg to the MindMed team. His leadership will strengthen o
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that members of the Company's management team will participate in the following investor conferences: Jefferies London Healthcare Conference Format: 1x1 Meetings Dates: November 20-21, 2024 Location: London, UK 7th Annual Evercore HealthCONx Conference Format: Fireside Chat and 1x1 Meetings Date and Time: Thursday, December 5, 2024 at 11:15 PM ET Location: Coral Gables, FL Webcast Link: 7th Annual Evercore HealthCONx Conference Audio webcasts and replays of av
Wedbush analyst Alicia Reese reiterates AMC Enter Hldgs (NYSE:AMC) with a Neutral and maintains $4 price target.
Investors with a lot of money to spend have taken a bearish stance on GameStop (NYSE:GME). And retail traders should know. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with GME, it often means somebody knows something is about to happen. So how do we know what these investors just did? Today, Benzinga's options scanner spotted 21 uncommon options trades for GameStop. This isn't normal. The overall sentiment of these big-money traders is split between 4% bullish and 90%, bearish. Out of all of the special optio
Roth MKM analyst Jason Wittes maintains Mind Medicine (NASDAQ:MNMD) with a Buy and maintains $36 price target.
GRAPEVINE, Texas, Nov. 18, 2024 (GLOBE NEWSWIRE) -- GameStop Corp. (NYSE:GME) ("GameStop" or the "Company") today announced that Nat Turner, Chairman and CEO of Collectors Holdings, Inc., has been appointed to the Company's Board of Directors. Contact GameStop Investor [email protected]
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the appointment of Gregg A. Pratt, Ph.D., as Chief Regulatory and Quality Assurance Officer. Dr. Pratt will serve as a member of the Executive Committee and oversee the Company's regulatory and quality functions, as well as its product registration strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241118653031/en/(Photo: Business Wire) "We are thrilled to welcome Gregg to the MindMed team. His leadership will strengthen o
Pitney Bowes Inc. (NYSE:PBI) ("Pitney Bowes" or the "Company"), a technology-driven company that provides SaaS shipping solutions, mailing innovation, and financial services to clients around the world, today announced the appointment of Lance Rosenzweig as the Company's permanent Chief Executive Officer ("CEO"), effective immediately. The Company's Board of Directors (the "Board") carried out an extensive CEO search process that was supported by a nationally recognized executive recruiting firm and included both internal and external candidates. After assessing Mr. Rosenzweig's considerable contributions as interim CEO and his track record of value creation at Pitney Bowes and at other co
4 - Mind Medicine (MindMed) Inc. (0001813814) (Issuer)
4 - Mind Medicine (MindMed) Inc. (0001813814) (Issuer)
4 - GameStop Corp. (0001326380) (Issuer)
4 - GameStop Corp. (0001326380) (Issuer)
4 - GameStop Corp. (0001326380) (Issuer)
4 - GameStop Corp. (0001326380) (Issuer)
Leerink Partners resumed coverage of MindMed with a rating of Outperform and set a new price target of $20.00
ROTH MKM initiated coverage of MindMed with a rating of Buy and set a new price target of $36.00
Robert W. Baird initiated coverage of MindMed with a rating of Outperform and set a new price target of $27.00
SC 13G/A - Mind Medicine (MindMed) Inc. (0001813814) (Subject)
SC 13G - AMC ENTERTAINMENT HOLDINGS, INC. (0001411579) (Subject)
SC 13G - AMC ENTERTAINMENT HOLDINGS, INC. (0001411579) (Subject)
--On track to initiate the Phase 3 Voyage study of MM120 Orally Disintegrating Tablet (ODT) in Generalized Anxiety Disorder (GAD) in the fourth quarter of 2024; 12-week topline data anticipated in the first half of 2026-- --On track to initiate the Phase 3 Panorama study of MM120 ODT in GAD and the Phase 3 Emerge study of MM120 ODT in Major Depressive Disorder (MDD) in the first half of 2025-- --Cash and cash equivalents of $295.3 million as of September 30, 2024, expected to fund operations into 2027 and extend at least 12 months beyond the first Phase 3 topline data readout for MM120 ODT in GAD-- --Company to host a conference call today at 4:30 p.m. EST-- Mind Medicine (MindMed) Inc.
Exceeds guidance with revenue of $62.4 million Scatter revenue up 35% year-over-year National CineMedia, Inc. (NASDAQ:NCMI) ("the Company" or "NCM"), the managing member and owner of approximately 100% of National CineMedia, LLC (NCM LLC), the operator of the largest cinema advertising network reaching movie audiences in the U.S., today announced its consolidated results for the fiscal third quarter ended September 26, 2024. "NCM delivered its fourth consecutive quarter of consistent results, achieving $62.4 million in revenue, and demonstrating our strength as the box office continues to accelerate," said Tom Lesinski, CEO of NCM. "We continue to drive meaningful growth in our premium P
National CineMedia, Inc. (NASDAQ:NCMI) ("the Company" or "NCM"), the managing member of National CineMedia, LLC ("NCM LLC"), the operator of the largest cinema advertising platform in the U.S., plans to issue its third quarter 2024 earnings results after the market closes on Tuesday, November 5, 2024. A conference call and audio webcast to discuss the results will take place at 5:00 p.m. Eastern Time. The conference call can be accessed by dialing (844) 481-2522 or for international participants (412) 317-0550. Participants should register at least 15 minutes prior to the commencement of the call. Additionally, a live audio webcast will be available to interested parties at www.ncm.com und
8-K - GameStop Corp. (0001326380) (Filer)
8-K - AMC ENTERTAINMENT HOLDINGS, INC. (0001411579) (Filer)
10-Q - Mind Medicine (MindMed) Inc. (0001813814) (Filer)